Full TitleA Multicenter, Open-Label Pilot Study of Follicular Lymphoma Ibrutinib Consolidation for FDG-PET Positivity After Frontline Chemoimmunotherapy (FLIPP)
Patients with evidence of cancer on a PET scan after initial treatment with rituximab and chemotherapy for follicular lymphoma have a high short-term risk of lymphoma recurrence. The usual treatment in this situation is surveillance and sometimes chemotherapy.
In this study, researchers want to see if the drug ibrutinib can convert active lymphoma visible on a PET scan to inactive. This might reduce the risk of follicular lymphoma in the future. Ibrutinib is a drug approved to treat three other types of blood cancer. It works by blocking a protein inside cancer cells called Bruton’s tyrosine kinase (BTK), which helps cancer cells to live and grow. Ibrutinib is a capsule that is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have follicular lymphoma that is visible on a PET scan after initial treatment with rituximab and chemotherapy.
- Patients must begin the study treatment at least 3 weeks but no more than 90 days after the completion of previous therapy.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.